{
    "xml": "<topic id=\"PHP7695\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/alitretinoin\" basename=\"alitretinoin\" title=\"ALITRETINOIN\">\n<title>ALITRETINOIN</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1124\" namespace=\"/interactions/list-of-drug-interactions/retinoids/alitretinoin\">Alitretinoin</xref>\n</p>\n<data name=\"vtmid\">409488005</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_527690857\" title=\"Retinoid and related drugs\">Retinoid and related drugs</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP74249\" outputclass=\"indicationsAndDose\" rev=\"1.30\" parent=\"/drugs/alitretinoin\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Severe chronic hand eczema refractory to potent topical corticosteroids</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult (prescribed by or under supervision of a consultant dermatologist)</p>\n<p>30&#8239;mg once daily; reduced if not tolerated to 10&#8239;mg once daily for 12&#8211;24 weeks total duration of treatment, discontinue if no response after 12 weeks, course may be repeated in those who relapse.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Severe chronic hand eczema refractory to potent topical corticosteroids in patients with diabetes, history of hyperlipidaemia, or risk factors for cardiovascular disease</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult (prescribed by or under supervision of a consultant dermatologist)</p>\n<p>Initially 10&#8239;mg once daily, increased if necessary up to 30&#8239;mg once daily for 12&#8211;24 weeks total duration of treatment, discontinue if no response after 12 weeks, course may be repeated in those who relapse.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74276\" outputclass=\"contraindications\" rev=\"1.7\" parent=\"/drugs/alitretinoin\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Hypervitaminosis A</ph>; <ph outputclass=\"contraindication\">uncontrolled hyperlipidaemia</ph>; <ph outputclass=\"contraindication\">uncontrolled hypothyroidism</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74288\" outputclass=\"cautions\" rev=\"1.12\" parent=\"/drugs/alitretinoin\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Avoid blood donation during treatment and for at least 1 month after stopping treatment</ph>; <ph outputclass=\"caution\">dry eye syndrome</ph>; <ph outputclass=\"caution\">history of depression</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74246\" outputclass=\"interactions\" rev=\"1.6\" parent=\"/drugs/alitretinoin\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (retinoids).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74237\" outputclass=\"sideEffects\" rev=\"1.12\" parent=\"/drugs/alitretinoin\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">anaemia</ph>; <ph outputclass=\"sideEffect\">arthralgia</ph>; <ph outputclass=\"sideEffect\">changes in thyroid function tests</ph>; <ph outputclass=\"sideEffect\">cheilitis</ph>; <ph outputclass=\"sideEffect\">conjunctivitis</ph>; <ph outputclass=\"sideEffect\">dry eyes</ph>; <ph outputclass=\"sideEffect\">dryness of lips</ph>; <ph outputclass=\"sideEffect\">dryness of skin</ph>; <ph outputclass=\"sideEffect\">erythema</ph>; <ph outputclass=\"sideEffect\">eye irritation</ph>; <ph outputclass=\"sideEffect\">flushing</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">myalgia</ph>; <ph outputclass=\"sideEffect\">raised creatine kinase</ph>; <ph outputclass=\"sideEffect\">raised serum concentration of triglycerides and of cholesterol (risk of pancreatitis if triglycerides above 9&#8239;mmol/litre)</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Ankylosing spondylitis</ph>; <ph outputclass=\"sideEffect\">asteototic eczema</ph>; <ph outputclass=\"sideEffect\">blurred vision</ph>; <ph outputclass=\"sideEffect\">cataracts</ph>; <ph outputclass=\"sideEffect\">epistaxis</ph>; <ph outputclass=\"sideEffect\">hyperostosis</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Benign intracranial hypertension</ph>; <ph outputclass=\"sideEffect\">vasculitis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Decreased tolerance to contact lenses</ph>; <ph outputclass=\"sideEffect\">depression</ph>; <ph outputclass=\"sideEffect\">impaired night vision</ph>; <ph outputclass=\"sideEffect\">keratitis</ph>; <ph outputclass=\"sideEffect\">mood changes</ph>; <ph outputclass=\"sideEffect\">suicidal ideation</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Dry eyes</p>\n<p>Dry eyes may respond to lubricating eye ointment or tear replacement therapy.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Benign intracranial hypertension</p>\n<p>Discontinue treatment if severe headache, nausea, vomiting, papilloedema, or visual disturbances occur.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74282\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/alitretinoin\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Effective contraception must be used.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Pregnancy prevention</p>\n<p>In women of child-bearing potential, exclude pregnancy 1 month before treatment, up to 3 days before treatment, every month during treatment (unless there are compelling reasons to indicate that there is no risk of pregnancy), and 5 weeks after stopping treatment&#8212;perform pregnancy test in the first 3 days of the menstrual cycle.</p>\n<p>Women must practise effective contraception for at least 1 month before starting treatment, during treatment, and for at least 1 month after stopping treatment. Women should be advised to use at least 1 method of contraception but ideally they should use 2 methods of contraception. Oral progestogen-only contraceptives are not considered effective. Barrier methods should not be used alone but can be used in conjunction with other contraceptive methods.</p>\n<p>Women should be advised to discontinue treatment and to seek prompt medical attention if they become pregnant during treatment or within 1 month of stopping treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74244\" outputclass=\"pregnancy\" parent=\"/drugs/alitretinoin\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;teratogenic.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74292\" outputclass=\"breastFeeding\" parent=\"/drugs/alitretinoin\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74257\" outputclass=\"hepaticImpairment\" parent=\"/drugs/alitretinoin\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74241\" outputclass=\"renalImpairment\" parent=\"/drugs/alitretinoin\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid in severe impairment&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74229\" outputclass=\"monitoringRequirements\" parent=\"/drugs/alitretinoin\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor serum lipids (more frequently in those with diabetes, history of hyperlipidaemia, or risk factors for cardiovascular disease)&#8212;discontinue if uncontrolled hyperlipidaemia.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61564\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.11\" parent=\"/drugs/alitretinoin\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Prescribing for women of child-bearing potential</p>\n<p>Each prescription for alitretinoin should be limited to a supply of up to 30 days' treatment and dispensed within 7 days of the date stated on the prescription.</p>\n<p>Alitretinoin is <b>teratogenic</b> and must <b>not</b> be given to women of child-bearing potential unless they practise effective contraception and then only after detailed assessment and explanation by the physician.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74242\" outputclass=\"patientAndCarerAdvice\" rev=\"1.21\" parent=\"/drugs/alitretinoin\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"patientResources\">\n<sectiondiv>\n<p>A patient information leaflet should be provided.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"patientAdviceInConceptionAndContraception\">\n<title>Patient advice required around conception and contraception</title>\n<sectiondiv>\n<p>Women of child-bearing potential must be counselled on pregnancy prevention.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74224\" outputclass=\"nationalFunding\" rev=\"1.17\" parent=\"/drugs/alitretinoin\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA177</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Alitretinoin for the treatment of severe chronic hand eczema in adults (August 2009)</p>\r\n<p>Alitretinoin is recommended for the treatment of severe chronic hand eczema that has not responded to potent topical corticosteroids. Treatment should be stopped as soon as an adequate response has been achieved (hands clear or almost clear), or if the eczema remains severe after 12 weeks, or if an adequate response has not been achieved by 24 weeks.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA177\">www.nice.org.uk/TA177</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP7695-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/alitretinoin\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76250\" title=\"Capsule\" namespace=\"/drugs/alitretinoin/capsule\">Capsule</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78311\" namespace=\"/treatment-summaries/eczema\" title=\"Eczema\" count=\"2\" rel=\"backlink\">Eczema</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1124\" namespace=\"/interactions/list-of-drug-interactions/retinoids/alitretinoin\" title=\"Alitretinoin\" count=\"1\" rel=\"link\">Alitretinoin</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76250\" namespace=\"/drugs/alitretinoin/capsule\" title=\"Capsule\" count=\"1\" rel=\"link\">Capsule</xref>\n</links>\n</topic>",
    "id": "PHP7695",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/alitretinoin",
    "basename": "alitretinoin",
    "title": "ALITRETINOIN",
    "interactants": [
        {
            "id": "bnf_int_1124",
            "label": "Alitretinoin"
        }
    ],
    "vtmid": "409488005",
    "drugClassification": [
        "Retinoid and related drugs"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Severe chronic hand eczema refractory to potent topical corticosteroids",
                        "html": "Severe chronic hand eczema refractory to potent topical corticosteroids"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "30 mg once daily; reduced if not tolerated to 10 mg once daily for 12&#8211;24 weeks total duration of treatment, discontinue if no response after 12 weeks, course may be repeated in those who relapse.",
                        "html": "<p>30&#8239;mg once daily; reduced if not tolerated to 10&#8239;mg once daily for 12&#8211;24 weeks total duration of treatment, discontinue if no response after 12 weeks, course may be repeated in those who relapse.</p>",
                        "ageGroup": "(prescribed by or under supervision of a consultant dermatologist)"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Severe chronic hand eczema refractory to potent topical corticosteroids in patients with diabetes, history of hyperlipidaemia, or risk factors for cardiovascular disease",
                        "html": "Severe chronic hand eczema refractory to potent topical corticosteroids in patients with diabetes, history of hyperlipidaemia, or risk factors for cardiovascular disease"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 10 mg once daily, increased if necessary up to 30 mg once daily for 12&#8211;24 weeks total duration of treatment, discontinue if no response after 12 weeks, course may be repeated in those who relapse.",
                        "html": "<p>Initially 10&#8239;mg once daily, increased if necessary up to 30&#8239;mg once daily for 12&#8211;24 weeks total duration of treatment, discontinue if no response after 12 weeks, course may be repeated in those who relapse.</p>",
                        "ageGroup": "(prescribed by or under supervision of a consultant dermatologist)"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Hypervitaminosis A",
                "html": "Hypervitaminosis A"
            },
            {
                "type": "contraindications",
                "textContent": "uncontrolled hyperlipidaemia",
                "html": "uncontrolled hyperlipidaemia"
            },
            {
                "type": "contraindications",
                "textContent": "uncontrolled hypothyroidism",
                "html": "uncontrolled hypothyroidism"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Avoid blood donation during treatment and for at least 1 month after stopping treatment",
                "html": "Avoid blood donation during treatment and for at least 1 month after stopping treatment"
            },
            {
                "type": "cautions",
                "textContent": "dry eye syndrome",
                "html": "dry eye syndrome"
            },
            {
                "type": "cautions",
                "textContent": "history of depression",
                "html": "history of depression"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (retinoids).",
                "html": "<p>Appendix 1 (retinoids).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "anaemia",
                        "html": "anaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "arthralgia",
                        "html": "arthralgia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "changes in thyroid function tests",
                        "html": "changes in thyroid function tests",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "cheilitis",
                        "html": "cheilitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "conjunctivitis",
                        "html": "conjunctivitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dry eyes",
                        "html": "dry eyes",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dryness of lips",
                        "html": "dryness of lips",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dryness of skin",
                        "html": "dryness of skin",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "erythema",
                        "html": "erythema",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "eye irritation",
                        "html": "eye irritation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "flushing",
                        "html": "flushing",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "myalgia",
                        "html": "myalgia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "raised creatine kinase",
                        "html": "raised creatine kinase",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "raised serum concentration of triglycerides and of cholesterol (risk of pancreatitis if triglycerides above 9 mmol/litre)",
                        "html": "raised serum concentration of triglycerides and of cholesterol (risk of pancreatitis if triglycerides above 9&#8239;mmol/litre)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Ankylosing spondylitis",
                        "html": "Ankylosing spondylitis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "asteototic eczema",
                        "html": "asteototic eczema",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "blurred vision",
                        "html": "blurred vision",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "cataracts",
                        "html": "cataracts",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "epistaxis",
                        "html": "epistaxis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hyperostosis",
                        "html": "hyperostosis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Benign intracranial hypertension",
                        "html": "Benign intracranial hypertension",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "vasculitis",
                        "html": "vasculitis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Decreased tolerance to contact lenses",
                        "html": "Decreased tolerance to contact lenses",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "depression",
                        "html": "depression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "impaired night vision",
                        "html": "impaired night vision",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "keratitis",
                        "html": "keratitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "mood changes",
                        "html": "mood changes",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "suicidal ideation",
                        "html": "suicidal ideation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Dry eyes",
                "textContent": "Dry eyes may respond to lubricating eye ointment or tear replacement therapy.",
                "html": "<p>Dry eyes may respond to lubricating eye ointment or tear replacement therapy.</p>"
            },
            {
                "type": "advice",
                "title": "Benign intracranial hypertension",
                "textContent": "Discontinue treatment if severe headache, nausea, vomiting, papilloedema, or visual disturbances occur.",
                "html": "<p>Discontinue treatment if severe headache, nausea, vomiting, papilloedema, or visual disturbances occur.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Effective contraception must be used.",
                "html": "<p>Effective contraception must be used.</p>"
            },
            {
                "type": "generalInformation",
                "title": "Pregnancy prevention",
                "textContent": "In women of child-bearing potential, exclude pregnancy 1 month before treatment, up to 3 days before treatment, every month during treatment (unless there are compelling reasons to indicate that there is no risk of pregnancy), and 5 weeks after stopping treatment&#8212;perform pregnancy test in the first 3 days of the menstrual cycle.\n\nWomen must practise effective contraception for at least 1 month before starting treatment, during treatment, and for at least 1 month after stopping treatment. Women should be advised to use at least 1 method of contraception but ideally they should use 2 methods of contraception. Oral progestogen-only contraceptives are not considered effective. Barrier methods should not be used alone but can be used in conjunction with other contraceptive methods.\n\nWomen should be advised to discontinue treatment and to seek prompt medical attention if they become pregnant during treatment or within 1 month of stopping treatment.",
                "html": "<p>In women of child-bearing potential, exclude pregnancy 1 month before treatment, up to 3 days before treatment, every month during treatment (unless there are compelling reasons to indicate that there is no risk of pregnancy), and 5 weeks after stopping treatment&#8212;perform pregnancy test in the first 3 days of the menstrual cycle.</p><p>Women must practise effective contraception for at least 1 month before starting treatment, during treatment, and for at least 1 month after stopping treatment. Women should be advised to use at least 1 method of contraception but ideally they should use 2 methods of contraception. Oral progestogen-only contraceptives are not considered effective. Barrier methods should not be used alone but can be used in conjunction with other contraceptive methods.</p><p>Women should be advised to discontinue treatment and to seek prompt medical attention if they become pregnant during treatment or within 1 month of stopping treatment.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;teratogenic.",
                "html": "<p>Avoid&#8212;teratogenic.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid.",
                "html": "<p>Manufacturer advises avoid.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;no information available.",
                "html": "<p>Manufacturer advises avoid&#8212;no information available.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid in severe impairment&#8212;no information available.",
                "html": "<p>Manufacturer advises avoid in severe impairment&#8212;no information available.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor serum lipids (more frequently in those with diabetes, history of hyperlipidaemia, or risk factors for cardiovascular disease)&#8212;discontinue if uncontrolled hyperlipidaemia.",
                "html": "<p>Monitor serum lipids (more frequently in those with diabetes, history of hyperlipidaemia, or risk factors for cardiovascular disease)&#8212;discontinue if uncontrolled hyperlipidaemia.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "title": "Prescribing for women of child-bearing potential",
                "textContent": "Each prescription for alitretinoin should be limited to a supply of up to 30 days' treatment and dispensed within 7 days of the date stated on the prescription.\n\nAlitretinoin is teratogenic and must not be given to women of child-bearing potential unless they practise effective contraception and then only after detailed assessment and explanation by the physician.",
                "html": "<p>Each prescription for alitretinoin should be limited to a supply of up to 30 days' treatment and dispensed within 7 days of the date stated on the prescription.</p><p>Alitretinoin is <b>teratogenic</b> and must <b>not</b> be given to women of child-bearing potential unless they practise effective contraception and then only after detailed assessment and explanation by the physician.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "patientResources": [
            {
                "type": "patientResources",
                "textContent": "A patient information leaflet should be provided.",
                "html": "<p>A patient information leaflet should be provided.</p>"
            }
        ],
        "patientAdviceInConceptionAndContraception": [
            {
                "type": "patientAdviceInConceptionAndContraception",
                "textContent": "Women of child-bearing potential must be counselled on pregnancy prevention.",
                "html": "<p>Women of child-bearing potential must be counselled on pregnancy prevention.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA177",
                        "label": "www.nice.org.uk/TA177"
                    }
                ],
                "fundingIdentifier": "NICE TA177",
                "textContent": "Alitretinoin for the treatment of severe chronic hand eczema in adults (August 2009) Alitretinoin is recommended for the treatment of severe chronic hand eczema that has not responded to potent topical corticosteroids. Treatment should be stopped as soon as an adequate response has been achieved (hands clear or almost clear), or if the eczema remains severe after 12 weeks, or if an adequate response has not been achieved by 24 weeks.\n\nwww.nice.org.uk/TA177",
                "html": "<p outputclass=\"title\">Alitretinoin for the treatment of severe chronic hand eczema in adults (August 2009)</p> <p>Alitretinoin is recommended for the treatment of severe chronic hand eczema that has not responded to potent topical corticosteroids. Treatment should be stopped as soon as an adequate response has been achieved (hands clear or almost clear), or if the eczema remains severe after 12 weeks, or if an adequate response has not been achieved by 24 weeks.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA177\">www.nice.org.uk/TA177</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76250",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78311",
                "label": "Eczema",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1124",
                "label": "Alitretinoin",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76250",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    }
}